公开(公告)号：US20180371542A1

公开(公告)日：2018-12-27

申请号：US16019091

申请日：2018-06-26

Applicant: MUSC Foundation for Research Development

Inventor： Raymond F. Anton

IPC: C12Q1/6876 ,  A61K31/485 ,  A61P25/32

Abstract: Provided are methods for treating alcohol use disorders using opioid receptor antagonists. In some embodiments, the presently disclosed methods include assaying nucleic acid from a subject regarding the subject's genotype with respect to the COMT and OPRM1 genes and administering or not administering an opioid receptor antagonist to the subject on the basis therefore. Also provided are methods for detecting susceptibility to an opioid receptor antagonist therapy for disorders associated with opioid receptor activity and methods for identifying and treating human subjects having susceptibility to opioid receptor antagonist therapies for disorders associated with opioid receptor activity.

公开(公告)号：US20180369238A1

公开(公告)日：2018-12-27

申请号：US16017781

申请日：2018-06-25

Applicant: MUSC Foundation for Research Development

Inventor： Raymond F. Anton ,  Joseph P. Schacht

IPC: A61K31/496 ,  A61P25/32

Abstract: Disclosed are methods for treating disorders associated with dopamine receptor activity. In some embodiments, the disclosed methods include assaying the nucleic acid from a subject for the genotype of the variable number tandem repeats (VNTR) polymorphism in the dopamine transporter DAT1/SLC6A3 gene, wherein when one or two alleles for 9 tandem repeats is detected a dopamine partial agonist is administered to the subject; and wherein when two alleles for 10 tandem repeats is detected a dopamine modulator is not administered to the subject. Also provided are methods for treating disorders associated with dopamine receptor activity that include genotyping a subject with respect to a COMT polymorphism, a DRD2 polymorphism, a 48-base-pair VNTR polymorphism in DRD4 exon 3, and/or a ANKK1 TaqA1 polymorphism, and methods for detecting susceptibility to dopamine modulator therapy for conditions associated with dopamine receptor activity.